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Columbus, OH, USAABSTRACT
Coronary artery disease (CAD) is a leading cause of death of women and men worldwide. CAD’s impact on
women traditionally has been underappreciated due to higher rates at younger ages in men. Microvascular
coronary disease disproportionately affects women. Women have unique risk factors for CAD, including
those related to pregnancy and autoimmune disease. Trial data indicate that CAD should be managed
differently in women. In this review, we will examine risk assessment for CAD in women, CAD’s impact
on women, as well as CAD’s female-speciﬁc presentation and management strategies.For far too long, many believed that coronary artery
disease (CAD) was primarily a “man’s disease.” With
increased awareness of the fact that the leading cause of
death in women is CAD, this notion is slowly eroding [1].
CAD is a common cause of death or disability in men and
women, but CAD manifests differently in women.
Furthermore, as women are being increasingly included in
CAD trials, management strategies speciﬁc to women are
emerging [2e6]. In this review, we summarize the current
state of knowledge about women and CAD. We will review
the impact of CAD on women, risk assessment, unique sex-
speciﬁc CAD characteristics, and management strategies
speciﬁc to women in 2013.From the *Department of
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CAD is the leading cause of death for both men and women
in the United States [7]. More women than men die of CAD
[7]. More women have died from CAD than of cancer
(including breast cancer), chronic lower respiratory disease,
Alzheimer disease, and accidents combined [7]. From 1998
to 2008, the rate of death attributable to CAD declined
30.6%, but the rates are increasing in young women (<55
years) [7,8]. CAD mortality is higher in women than in men
[7]. Of particular concern is the rise in obese American
individuals, with its subsequent impact on diabetes and
future development of CAD. The prevalence of obesity is
similar in men and women, at 34% of the American pop-
ulation, according to NHANES (National Health and
Nutrition Examination Survey) 2007 to 2008 [9]. However,
the impact of obesity on the development of CAD appears to
be greater in women than in men. Among individuals in the
Framingham Heart Study, obesity increased the relative risk
of CAD by 64% in women, as opposed to 46% in men [10].
The average age at ﬁrst myocardial infarction (MI) is 64.5
years for men and 70.3 years for women [7]. The incidence of
CAD in women lags behind men by 10 years and by 20 years
for more serious clinical events such as MI and sudden deathGLOBAL HEART, VOL. 8, NO. 2, 2013
June 2013: 105-112[11]. The consequences of CAD are worse in women than in
men. Among individuals with premature MI (under age 50),
women experience a 2-foldhighermortality rate after acuteMI
compared tomen [12]. Among older individuals (over the age
of 65), women are more likely to die within the ﬁrst year after
MI [7]. In individuals 45 to 64 years of age, women are more
likely than men to have heart failure within 5 years of MI [7].
Women have higher rates of angina than do men [7,13]. A
female excess of anginal prevalence was demonstrated in
a meta-analysis of data from 31 widely varied countries,
including non-English speaking countries [13]. The pooled
sex ratio of angina prevalence was 1.20 (95% conﬁdence
interval: 1.14 to 1.28, p < 0.0001) and was true of pre-
menopausal and post-menopausal women [13].
The burden of CAD is high among women. However,
it appears that the pathophysiology of CAD varies between
women and men. On cardiovascular computed tomog-
raphy, women have been shown to have smaller coronary
artery diameters than men do [14]. Women are less likely
than men are to have obstructive CAD at the time of
coronary angiography [15,16]. Despite the lack of
obstructive CAD visualized on cardiac catheterization at
the time of acute coronary syndrome (ACS), the prognosis
of these women is not benign. Over one-half of symp-
tomatic women without obstructive CAD continue to have
signs and symptoms of ischemia and to undergo repeat
hospitalization and coronary angiography [17,18].
Recently, disorders of the coronarymicrovasculature and
endothelial dysfunction have been implicated in the occur-
rence of nonobstructive CAD in women. Han et al. [19]
studied men and women with early CAD and found that
men have higher degrees of atheroma and epicardial endo-
thelial dysfunction, whereas women have more disease of the
microvasculature. Retinal artery narrowing has been shown to
be a marker for microvascular disease, and in the ARIC
(Atherosclerosis Risk in Communities Study) population,
a decrease in retinal artery narrowing assessed on retinal
photographs corresponded to an increase in CAD incidence105
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a more prominent role of microvascular disease in CAD
pathophysiology in women as opposed to men [20]. In
addition, autopsy data has shown that women have a greater
frequency of coronary plaque erosion and distal embolization
[21]. In theWISE (Women’s Ischemia Syndrome Evaluation)
study, approximately one-half of women with chest pain
without obstructive CAD had microvascular dysfunction
[22]. In a study of post-menopausal women, impairment of
ﬂow-mediated dilation of the brachial artery predicted the
development of cardiovascular events [23]. Hypertensive
post-menopausal women were treated with antihypertensive
therapy with both an improvement in ﬂow-mediated vaso-
dilation and an associated improvement in cardiovascular
events [24]. Given the occurrence of CAD in women without
obstructive CAD, the phrase “female-speciﬁc ischemic heart
disease” has been recommended when discussing disease of
the coronary arteries in women [25].RISK ASSESSMENT IN WOMEN
There are multiple ways to assess an asymptomatic wom-
an’s risk. The “2010 American College of Cardiology/
American Heart Association Guideline for Assessment of
Cardiovascular Risk in Asymptomatic Adults” recommends
obtaining a Framingham-like (global) risk score that
incorporates multiple traditional cardiovascular risk factors
for all asymptomatic adults without a history of CAD as
a class I indication [26].
The “Effectiveness-Based Guidelines for the Prevention
of Coronary Artery Disease in Women—2011 Update”
recommends risk-stratifying women based on their risk
scores into 3 categories: 1) high risk; 2) at risk; and 3)
optimal risk [27]. High-risk individuals include all women
with known CAD, peripheral arterial disease, symptomatic
carotid artery disease, abdominal aortic aneurysm, end-
stage or chronic kidney disease, or who have a 10-year
predicted CAD risk 10%. At-risk status is deﬁned as
having 1 or more of the following risk factors: cigarette
smoking; systolic blood pressure 120 mm Hg, diastolic
blood pressure 80 mm Hg, or treated hypertension; total
cholesterol >200 mg/dl, high-density lipoprotein choles-
terol <50, or treated dyslipidemia; obesity (particularly
central adiposity); poor diet; physical inactivity; family
history of premature CAD occurring in ﬁrst-degree
relatives in men <55 years of age or in women <65
years of age; metabolic syndrome; evidence of advanced
subclinical atherosclerosis (e.g., coronary calciﬁcation,
carotid plaque, or thickened intima-media thickness); poor
exercise capacity on treadmill test and/or abnormal heart
rate recovery after stopping exercise; systemic autoimmune
collagen-vascular disease (e.g., lupus or rheumatoid
arthritis); or history of pre-eclampsia, gestational diabetes,
or pregnancy-induced hypertension. Optimal risk is
deﬁned as having all of the following factors: total
cholesterol <200 mg/dl (untreated); blood pressure <120/
<80 mm Hg (untreated); fasting blood glucose <100 mg/dl (untreated); body mass index <25 kg/m2; abstinence
from smoking and a healthy (DASH [Dietary Approaches
to Stop Hypertension]-like) diet (Table 1) [27].
Traditional risk factors such as age, family history of
CAD, hypertension, diabetes, dyslipidemia, smoking, and
physical inactivity are important predictors of risk in
women. In contrast to the linear increase in CAD in men as
they age, there is a more exponential increase in CAD in
women after the age of 60 [28]. The NCEP ATP III (National
Cholesterol Education Panel Adult Treatment Panel III)
considers the age of 55 years or above to be a risk factor for
women, compared with 45 years for men. Irrespective of
this, there is higher mortality among younger women, as
opposed to men, with acute MI [12]. Premature CAD in
a ﬁrst-degree female relative is a relatively more potent risk
factor than is premature CAD in male relatives [29].
Hypertension ismore prevalent inwomen, particularly older
women [30].Womenwith hypertension have a higher risk of
developing congestive heart failure than men do [31]. The
presence of diabetes is a relatively greater risk factor for CAD
in women versus men, increasing a woman’s risk of CAD by
3- to 7-fold, with only a 2- to 3-fold increase in diabetic men
[32]. Furthermore, women with diabetes have a greater than
3-fold increase in CAD risk than nondiabetic women do
[32]. After the ﬁfth decade of life, women have higher
cholesterol levels than men do [33]. Elevated triglycerides
have been shown to be of greater risk to women than to men
[34e36]. Lack of physical ﬁtness is a predictor of mortality.
In the St. James Women Take Heart Project, asymptomatic
women who were unable to achieve 5 metabolic equivalents
(MET) on a Bruce protocol have a 3-fold increased risk of
death compared with women who achieved >8 MET, even
after controlling for traditional risk factors [37]. Focus on
risk factors is important in the prevention of CAD inwomen,
just as it is in men. When women with 2 or more risk factors
were compared towomenwith no risk factors, those without
risk factors had a substantially lower lifetime risk of CAD
(8.2% vs. 50.2%) [38].
Addressing those risk factors that are unique to women
is also important. Though it is unclear if high-sensitivity
C-reactive protein (hsCRP) is an independent risk factor
for CAD, it may improve risk detection in women [39e41].
HsCRP may add prognostic information in women with
metabolic syndrome. In 1 study [42] of apparently healthy
women, those women with the metabolic syndrome
and a baseline hsCRP >3.0 mg/l had almost twice the
risk of future cardiovascular events than did those with
metabolic syndrome and a hsCRP <3.0 mg/l. The
Reynolds risk score, a risk assessment tool, incorporates
hsCRP and has been shown to improve risk prediction in
women [43].
Calcium scoring has been shown to improve risk
prediction in women. In MESA (Multi-Ethnic Study of
Atherosclerosis), 3,601 women were studied, and 90%were
classiﬁed as low risk. Prevalence of any coronary calciumwas
associated with a 6-fold increased risk of CAD, adjusted for
age, ethnicity, body mass index, low-density lipoprotein,GLOBAL HEART, VOL. 8, NO. 2, 2013
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TABLE 1. Classiﬁcation of CAD risk in women
Risk Status Criteria
High risk (1 high-risk state)  Clinically manifest CHD
 Clinically manifest cerebrovascular disease
 Clinically manifest peripheral arterial disease
 Abdominal aortic aneurysm
 End-stage or chronic kidney disease
 Diabetes mellitus
 10-year predicted CAD risk >10%
At risk (>1 risk factor)  Cigarette smoking
 SBP >120 mm Hg, DBP >80 mm Hg, or treated hypertension
 Total cholesterol >200 mg/dl, HDL-C <50 mg/dl, or treated for dyslipidemia
 Obesity, particularly central adiposity
 Poor diet
 Physical inactivity
 Family history of premature CAD occurring in ﬁrst-degree relatives in men <55
years of age or in women <65 years of age
 Metabolic syndrome
 Evidence of advanced subclinical atherosclerosis (e.g., coronary calciﬁcation,
carotid plaque, or thickened IMT)
 Poor exercise capacity on treadmill test and/or abnormal heart rate recovery
after stopping exercise
 Systemic autoimmune collagen-vascular disease (e.g., lupus or rheumatoid
arthritis)
 History of pre-eclampsia, gestational diabetes, or pregnancy-induced
hypertension
Ideal coronary artery health (all of these)  Total cholesterol <200 mg/dl (untreated)
 BP <120/<80 mm Hg (untreated)
 Fasting blood glucose <100 mg/dl (untreated)
 Body mass index <25 kg/m2
 Abstinence from smoking
 Healthy (DASH-like) diet
CAD, coronary artery disease; CHD, coronary heart disease; DASH, Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; HDL-C,
high-density lipoprotein cholesterol; IMT, intima-media thickness; SBP, systolic blood pressure.
Adapted, with permission, from Mosca et al. [27].
gREVIEWjhigh blood pressure, smoking, estrogen, and statin therapy.
A calcium score of 300 was associated with an 8.6%
absolute risk of CAD. The presence of coronary calcium
therefore redeﬁned a group of women improperly labeled as
low risk by Framingham criteria [44].
Autoimmune diseases are more prevalent in women
and have been implicated in higher CAD risk. Rheumatoid
arthritis and systemic lupus erythematosus (SLE) have
been associated with a signiﬁcantly increased relative risk
for CAD [45]. Women in the Framingham Offspring Study
ages 34 to 44 years with SLE were 50 more likely to have
an acute MI than were women of the same age without SLE
[46]. This increased CAD burden in women with SLE has
been demonstrated in other studies, including 1 study of
women with SLE who underwent single-photon emission
computed tomography (SPECT), and the presence of
myocardial perfusion defects was independently associated
with an increased risk of CAD, beyond the Framingham
risk score alone [47]. In a longitudinal study of patientsGLOBAL HEART, VOL. 8, NO. 2, 2013
June 2013: 105-112with lupus, serial carotid ultrasounds demonstrated that
28% had progressive atherosclerosis over a 34-month
follow-up period, averaging approximately a 10%
progression per year [48].
Unique to women are the hormonal changes that occur
over their lifetimes and ultimately affect CAD risk.
Dysfunction in ovulation has been associated with
increased CAD risk. A meta-analysis found that women
with polycystic ovarian syndrome have an increased
prevalence of impaired glucose tolerance, metabolic
syndrome, and diabetes when compared with women
without polycystic ovarian syndrome [49]. Functional
hypothalamic amenorrhea, a cause of ovarian dysfunction,
has been shown to be associated with premature coronary
atherosclerosis [50]. Early age at menarche (<12 years) is
also associated with increased risk of CAD events, CAD
mortality, and overall mortality in women, and the
association appeared to be only partly mediated by
increased adiposity [51].107
FIGURE 1. Nomogram to calculate percent of predicted
exercise capacity for age for men and women.
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risk of subsequent ischemic heart disease, stroke, and venous
thromboembolic events over the 5 to 10 years following the
pregnancy [52]. Gestational diabetes increases the risk for
future diabetes [53], thereby increasing the risk for future
CAD. Accordingly, a history of pre-eclampsia or gestational
diabetes categorizes a woman as “at risk” for CAD, based on
the 2011 “Effectiveness-Based Guidelines for Prevention of
CAD in Women” [27]. Another risk factor to consider in
women is the effect of breast cancer therapy on future CAD
risk. As was recently reported, although advances in breast
cancer therapies are improving survival in early breast cancer,
the gains are being attenuated by increasing CAD risk [54].
Whether the increased CAD risk is due to the breast cancer
therapies or to the disease itself (which is associatedwith some
of the same risk factors for CAD) remains unknown.Constructing a line from the patient’s achieved metabolic
equivalents (METs) in an exercise stress test and age will
intersect with the patient’s percentage of predicted exer-
cise capacity for age, based on sex. Established using the
following regression lines based on age and sex: Men:
Predicted METs¼ 14.7 (0.11 age); Women: Predicted
METs ¼ 14.7  (0.13  age). Adapted, with permission,
from Gulati et al. [58].DIAGNOSIS OF MYOCARDIAL ISCHEMIA IN
WOMEN
An exercise stress test is used commonly in the evaluation
of suspected CAD. In women, ST-segment depression
noted on exercise stress testing is felt to be less accurate
than it is in men; in women, the sensitivity and speciﬁcity
of ST-segment depression is lower than in men [55]. The
negative predictive value is high in both men and women,
however [56]. A negative exercise stress test, therefore, can
effectively rule out the diagnosis of CAD in women. The
Duke treadmill score, which incorporates exercise time,
ST-segment deviation, and an anginal score, is particularly
useful in women and performs better in women than in
men for predicting signiﬁcant CAD [57]. Exercise is
a powerful predictor of CAD. Importantly, a nomogram
has been established deﬁning age-predicted exercise
capacity in women (Fig. 1) [58]. As mentioned earlier,
women who are unable to reach 5 METs or perform <85%
of age-predicted ﬁtness level on an exercise stress test have
a higher risk of MI and all-cause mortality [37,58].
Stress echocardiography has similar high levels of
sensitivity and speciﬁcity in women and men [59,60]. Its
lack of radiation is particularly attractive in younger women.
Myocardial perfusion imaging using SPECT has been well
studied in women. The incorporation of technetium-99
sestamibi radiotracer and the use of gating technology have
improved the sensitivity and speciﬁcity of SPECT imaging in
women to nearly 90% (Table 2) [61e78]. SPECT stress
imaging effectively risk-stratiﬁes women [79e81]. In
women with a normal myocardial perfusion study using
SPECT imaging, the annual CAD death rate is very low
(0.6%/year), in contrast to a much higher event rate (5%/
year) in those with abnormal myocardial perfusion [81].
There is increasing interest in the use of stress cardiac
magnetic resonance (CMR) imaging in the assessment of
women. A recent study of predominantly female patients
with chest pain and nonobstructive CAD who underwent
adenosine CMR found that subendocardial ischemia was
frequently present when compared with images of controlsubjects [82]. In women with ACS and normal coronary
arteries who underwent CMR, abnormalities on late gado-
linium enhancement consistent with ischemia were
frequently noted [83]. In a small substudy from the WISE
cohort, women with nonobstructive CAD with an abnormal
stress-induced CMR had an increase in adverse cardiovas-
cular events [84]. CMR and its applications to women and
CAD are only beginning to be explored; much remains to be
learned about CMR’s prognostic implications.
MANAGEMENT OF OBSTRUCTIVE CAD IN WOMEN
Why is mortality due to ACS higher in women than in men
[7]? Trials and registry studies suggest women with ACS are
treated less aggressively thanmen are. In theCRUSADE (Can
Rapid Risk Stratiﬁcation of Unstable Angina Patients
Suppress Adverse Outcomes With Early Implementation of
the American College of Cardiology/American Heart Asso-
ciation Guidelines) initiative [85], women were less likely to
receive heparin and glycoprotein (GP) IIb/IIIa inhibitors and
less likely to undergo cardiac catheterization and revascu-
larization than men were. Women with ACS have also been
shown to be less likely to receive early aspirin, beta-blockers,
reperfusion, and timely reperfusion [86].
Strategies for ACS may have different efﬁcacy in women
than inmen. Ameta-analysis of randomized controlled trials
of ACS showed that an invasive strategy was more beneﬁcial
in women with positive biomarkers in contrast to women
with negative biomarkers; such a difference was not seen in
men [2]. After percutaneous coronary intervention, women
have been shown to have a higher mortality in ST-segment
elevation and noneST-segment elevation MI [87].GLOBAL HEART, VOL. 8, NO. 2, 2013
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TABLE 2. Diagnostic value of various stress testing modalities in women
Stress Testing Modality Sensitivity, % Speciﬁcity, %
Negative Predictive
Value
Positive Predictive
Value
Exercise ECG [63e68] 31e71 66e78 78 47
Exercise echocardiography [68e70] 80e88 79e86 98 74
Exercise SPECT [71e74] 78e88 64e91 99 87
Pharmacological echocardiography [75e77] 76e90 85e94 68 94
Pharmacological SPECT [61,62,78] 80e91 65e86 90 68
ECG, electrocardiogram; SPECT, single-photon emission computed tomography.
Adapted, with permission, from Kohli and Gulati [60].
gREVIEWjFurthermore, in ACS patients, women without raised
biomarkers did not beneﬁt from GP IIb/IIIa inhibitors,
unlike men; when women had raised biomarkers, they did
receive a risk reduction with GP IIb/IIIa inhibitors [3].
Women were found in 1 trial [88] to experience higher rates
of bleeding with percutaneous intervention; however, this
has been shown to be largely attributable to body size and
renal function.
Several recent trials have speciﬁcally examined drug-
eluting stent placement in men and women and, overall,
have found similar outcomes after stent placement [89,90].
Among patients undergoing coronary artery bypass
grafting (CABG), however, female sex is an independent
risk factor for morbidity and mortality. Women have
a higher risk of morbidity and mortality and they experi-
ence less relief from angina than do men after CABG,
despite comprising less than 30% of the CABG population
[4,5]. Interestingly, this sex discrepancy appears to be
reduced when an off-pump CABG is performed [91].MANAGEMENT OF NONOBSTRUCTIVE CORONARY
DISEASE IN WOMEN
Among women with symptoms of myocardial ischemia
who have been demonstrated to have angiographically
nonobstructive CAD, the prognosis was initially felt to be
benign [92,93]. However, more recent data have shown
that the prognosis is not benign and the risk of cardio-
vascular events is higher than it is for asymptomatic
women [18,94]. Patients with unstable angina and no
critical coronary obstruction still had a 2% risk of death
and MI at 30 days after MI [95]. Among women with
persistent chest pain but no obstructive CAD at cardiac
catheterization for suspected ACS, cardiovascular
outcomes were worse in those with continued chest pain
[17]. Symptomatic women in the WISE study with non-
obstructive CAD (lesions 1% to 49%) had a CAD event
rate of 16% versus only 7.9% in women with no CAD and
only 2.4% in asymptomatic age- and race-matched control
subjects [94].
The focus of treatment of nonobstructive CAD has been
on symptom improvement or vascular function response.
Statins and angiotensin-converting enzyme inhibitors have
been shown to improve endothelial function and symptoms
[96e99]. Statins have been demonstrated to improveGLOBAL HEART, VOL. 8, NO. 2, 2013
June 2013: 105-112microcirculation [100]. Chest pain syndromes have been
effectively treated with beta-blockers [101]. Imipramine has
been shown to improve symptoms inwomenwith chest pain
and nonobstructive CAD, possibly related to a visceral
analgesic effect [102]. L-arginine has been shown to improve
endothelial function and symptoms in patients with non-
obstructive CAD [103], although concerns about its safety
have arisen [104]. The effects of ranolazine are promising.
A recent pilot study demonstrated that women with angina,
myocardial ischemia, and no obstructive CAD had an
improvement in angina with ranolazine [6]. Randomized
control data on women with chest pain and nonobstructive
CAD are currently lacking; further research in this area is
needed.
THE UNDERTREATMENT OF CAD IN WOMEN
Awareness of the tremendous effect CAD has on women is
slowly increasing. In 1997, only 30% of American women
surveyed were aware that the leading cause of death in
women is CAD; this increased to 54% in 2009 [1]. In
a survey performed in 2004, fewer than 1 in 5 physicians
recognized that more women than men die each year from
CAD [105]. Unfortunately, women are less likely to receive
preventive recommendations, such as lipid-lowering
therapy, aspirin, and lifestyle advice, than are similarly
scoring Framingham-risk men [105,106]. Hypertensive
women are less likely to have their blood pressure at goal
[107]. Women are less likely to be treated to reach goal
for low-density lipoprotein cholesterol [108]. Female
diabetics, the group at highest risk for CAD, have the
greatest sex disparity in achieving low-density lipoprotein
cholesterol targets [109]. Cardiac rehabilitation after MI is
underused, particularly in women, as demonstrated in
numerous national studies [110e113]. Women are 55%
less likely to participate in cardiac rehabilitation than men
are [110].
SUMMARY
Women are affected by CAD in large numbers and to a large
degree. CAD is the leading cause of mortality in women. The
manifestation of CAD has unique characteristics in women.
Increasing data demonstrate that some treatment strategies
have sex-speciﬁc effectiveness. Further research regarding
the pathophysiology of CAD in women, diagnosis, and109
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110treatment strategies speciﬁc to women is required. CAD is
not a “man’s only” disease, and we eagerly await future
studies that examine its unique presence in women.REFERENCES
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